Display Settings:

Format

Send to:

Choose Destination
Hum Vaccin Immunother. 2012 Dec 1;8(12):1746-57. doi: 10.4161/hv.21689. Epub 2012 Aug 16.

Therapeutic vaccination to treat chronic infectious diseases: current clinical developments using MVA-based vaccines.

Author information

  • 1Transgene, Department of Infectious Diseases, Centre d'Infectiologie, Lyon, France.

Abstract

A famous milestone in the vaccine field has been the first successful vaccination against smallpox, in 1798, by Edward Jenner. Using the vaccinia cowpox virus, Jenner was able to protect vaccinees from variola or smallpox. The Modified Virus Ankara (MVA) poxvirus strain has been one of the vaccines subsequently developed to prevent smallpox infection and was selected by the US government in their Biodefense strategy. Progress in molecular biology and immunology associated with MVA infection has led to the development of MVA as vaccine platform, both in the field of preventive and therapeutic vaccines. This later class of therapeutics has witnessed growing interest that has translated into an increasing number of vaccine candidates reaching the clinics. Among those, MVA-based therapeutic vaccines have addressed four major chronic infections including viral hepatitis, AIDS, human papillomavirus-linked pathologies and tuberculosis. Clinical trials encompass phase 1 and 2 and have started to show significant results and promises.

KEYWORDS:

clinical trials; infectious diseases; modified virus ankara; poxvirus; therapeutic vaccines

PMID:
22894957
[PubMed - indexed for MEDLINE]
PMCID:
PMC3656061
Free PMC Article

Images from this publication.See all images (4)Free text

PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Landes Bioscience Icon for PubMed Central
    Loading ...
    Write to the Help Desk